Acute changes in morphology and renal vascular relaxation function after renal denervation using temperature-controlled radiofrequency catheter

[1] Dzau VJ(2006)The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part i: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) Circulation 114 2850-2870

[2] Antman EM(2009)Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 1275-1281

[3] Black HR(2011)Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months Hypertension 57 911-917

[4] Hayes DL(2014)2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8) Jama 311 507-520

[5] Manson JE(2011)Prevalence of resistant hypertension in the United States, 2003-2008 Hypertension 57 1076-1080

[6] Plutzky J(2012)Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity Front Physiol 3 29-1088

[7] Popma JJ(2000)Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function Hypertension 36 1083-1057

[8] Stevenson W(2011)Sympatho-renal axis in chronic disease Clinical research in cardiology : official journal of the German Cardiac Society 100 1049-1909

[9] Krum H(2010)Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): a randomised controlled trial Lancet 376 1903-2140

[10] Schlaich M(2013)Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the enlightn i trial Eur Heart J 34 2132-1759

[1] Dzau VJ(2006)The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part i: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) Circulation 114 2850-2870

[2] Antman EM(2009)Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 1275-1281

[3] Black HR(2011)Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months Hypertension 57 911-917

[4] Hayes DL(2014)2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8) Jama 311 507-520

[5] Manson JE(2011)Prevalence of resistant hypertension in the United States, 2003-2008 Hypertension 57 1076-1080

[6] Plutzky J(2012)Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity Front Physiol 3 29-1088

[7] Popma JJ(2000)Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function Hypertension 36 1083-1057

[8] Stevenson W(2011)Sympatho-renal axis in chronic disease Clinical research in cardiology : official journal of the German Cardiac Society 100 1049-1909

[9] Krum H(2010)Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): a randomised controlled trial Lancet 376 1903-2140

[10] Schlaich M(2013)Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the enlightn i trial Eur Heart J 34 2132-1759